Tauroursodeoxycholate dihydrate(Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Tauroursodeoxycholate dihydrate (Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate) 纯度: ≥98.0%

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate 是一种内质网应激抑制剂。Tauroursodeoxycholate 显著降低凋亡分子如 caspase-3caspase-12 表达。Tauroursodeoxycholate 也抑制 ERK

Tauroursodeoxycholate dihydrate(Synonyms: 牛磺熊去氧胆酸二水合物; Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate)

Tauroursodeoxycholate dihydrate Chemical Structure

CAS No. : 117609-50-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥660 In-stock
50 mg ¥600 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Tauroursodeoxycholate dihydrate 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Metabolism/Protease Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Glutamine Metabolism Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Angiogenesis Related Compound Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].

IC50 & Target

ERK[1]
Caspase-3, Caspase-12[2]

Clinical Trial

分子量

535.73

Formula

C26H49NO8S

CAS 号

117609-50-4

中文名称

牛磺熊脱氧胆酸二水合物;牛磺熊去氧胆酸二水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (155.54 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8666 mL 9.3331 mL 18.6661 mL
5 mM 0.3733 mL 1.8666 mL 3.7332 mL
10 mM 0.1867 mL 0.9333 mL 1.8666 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.88 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.

    [2]. Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务